Archana T. Laroia

Archana T. Laroia

Auto-generated profile, based on publicly available information

Archana T. Laroia

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
KOKathryn M. Olsen
Kathryn M. Olsen
SMShawdi Manouchehr-Pour
Shawdi Manouchehr-Pour
EDEdwin F. Donnelly
Edwin F. Donnelly
THTravis S. Henry
Travis S. Henry
MBMark F. Berry
Mark F. Berry
JKJeffrey P. Kanne
Jeffrey P. Kanne

25 November 2019 in Journal of Digital Imaging
Verified
Journal Article
Closed access
PDF file
RFRoss W. Filice
Ross W. Filice
ASAnouk Stein
Anouk Stein
CWCarol C. Wu
Carol C. Wu
VAVeronica A. Arteaga
Veronica A. Arteaga
SBStephen Borstelmann
Stephen Borstelmann
GSGeorge Shih
George Shih

1 September 2011 in Ultrasound Quarterly
Verified
Journal Article
Closed access
MAMonzer M. Abu-Yousef
Monzer M. Abu-Yousef
JLJoshua H. Larson
Joshua H. Larson
DKDavid M. Kuehn
David M. Kuehn
AWAndrew S. Wu
Andrew S. Wu
ALArchana T. Laroia
Archana T. Laroia
We examined records of patients who underwent ultrasound-guided fine needle aspiration biopsy (USGFNAB) of neck lesions to determine whether there was a significantly increased incidence of bleeding complications in patients on antithrombotic and/or anticoagulant (AT/AC) medications compared to patients not receiving AT/AC therapy. Our institutional review board approved this Health Insurance Portability and Accountability Act-compliant retrospective examination of patients' medical data without requiring informed consent. The records of 593 patients (422 women and 171 men ranging from 18 to 91 years of age) who underwent USGFNAB of 788 total neck lesions over an 18-month period were reviewed to determine AT/AC medication used and evidence of USGFNAB-related bleeding complications. Of these, 144 patients (24.3%) were taking one or more AT/AC medications including aspirin, clopidogrel, heparin, and warfarin. The χ2 test was used to assess statistically significant differences in the incidence of USGFNAB-related bleeding complications between patients who were on daily AT/AC medications (test group) and patients who were not (control group). Six USGFNAB-related hematomas (1.0%) occurred. Two hematomas developed in patients on AT/AC medications, and 4 hematomas developed in patients who did not take AT/AC medications (χ2 = 0.27, df = 1, P = 0.603). This study shows no statistically significant difference in the incidence of hematoma formation after USGFNAB of neck lesions in patients taking AT/AC medications compared to patients not taking AT/AC medications. On the basis of these data, there is no benefit, with regard to incidence of bleeding complications, to discontinuing AT/AC medications in patients undergoing USGFNAB of neck masses.

1 November 2015 in Academic Radiology
Verified
Journal Article
Closed access
KBKevin S. Berbaum
Kevin S. Berbaum
EKElizabeth A. Krupinski
Elizabeth A. Krupinski
KSKevin M. Schartz
Kevin M. Schartz
RCRobert T. Caldwell
Robert T. Caldwell
MMMark T. Madsen
Mark T. Madsen
EFEdmund A. Franken
Edmund A. Franken

1 March 2003 in International Journal of Cardiology
Verified
Journal Article
Closed access
SLSandeep T. Laroia
Sandeep T. Laroia
AGApar Kishor Ganti
Apar Kishor Ganti
ALArchana T. Laroia
Archana T. Laroia
KTKetki K. Tendulkar
Ketki K. Tendulkar

1 January 2010 in World Journal of Radiology
Verified
Journal Article
Open access
ALArchana T Laroia
Archana T Laroia
BTBrad H Thompson
Brad H Thompson
SLSandeep T Laroia
Sandeep T Laroia
EBEdwin Jr van Beek
Edwin Jr van Beek
Modern imaging of the tracheo-bronchial tree